文档介绍：结外NK/T细胞淋巴瘤,鼻型(Extranodal NK/T-cell lymphoma,nasal type)
福建省肿瘤医院 杨瑜
未成熟NK细胞
母细胞性浆细胞样树状突细胞肿瘤
（以前称为母细胞性NK细胞白血病/受累（N1-N3，非M1）
分四个危险组：group 1, no
group 2, one factor;
group 3, two factors;
group 4, three or four
J Clin Oncol 24:612-618. © 2006 by American Society of Clinical Oncology
1 低危
2 低中危
3 中高危
4 高危
group 1：%
group 2：%
group 3：%
group 4：%
5年OS
IPI不能区分：低危与低中危
中高危与高危
76%
0%
结论：新的预后模型比国际预后指数
能更好区分和预测结外NK/T细
胞淋巴瘤预后。
K-PI
治疗
Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma
Early stage (stage IE: 51, stage IIE: 13) nasal NK/T-cell lymphoma (NNTCL)
23 received radiotherapy (RT) alone, 41 cases were treated with radiochemotherapy (RCT)
1–6 cycles of anthracycline-based chemotherapeutic regimens.
Med Oncol (2010) 27:798–806
%
%
Fig. 2 The survival status of all
patients according to treatment
modality. (a) OS. (b) PFS. RT
radiotherapy alone, RCT
radiochemotherapy
%
%
P=
结论：化疗联合放疗不能改善早期鼻的NK/T
细胞淋巴瘤的生存
Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211
入组：33例新诊断局限期鼻的NK/T细胞淋巴瘤
放疗剂量：ⅠE期 50GY；ⅡE期
化疗方案：DeVIC 3疗程
登记入组后7天内同时开始
J Clin Oncol 27:5594-5600. © 2009
Level 1
Level 2
DXM
40mg
40mg
D1-3
VP16
67mg/m2
100mg/m2
D1-3
IFO
D1-3
CBP
200mg/m2
300mg/m2
D1
4药联用，三周重复，连用3疗程
DeVIC方案
Fig 1. (A) Overall survival and (B) progression-free survival
of patients treated with radiotherapy and two thirds dose of
dexamethasone, etoposide, ifosfamide, and carboplatin.
78%
67%
历史对照：单用放疗OS 45%
Fig 2. Effect of complete response (CR) on (A) overall
survival and (B) progression-free survival of patients treated
with radiotherapy and two thirds dose of dexamethasone,
etoposide, ifosfamide, and